Fosun group returns to M&A with planned bid for India firm

Shanghai Fosun Pharmaceutical (Group) Co has made a non-binding proposal to buy India’s Gland Pharma, which is backed by KKR and valued at up to $1.5bn, to boost its drug manufacturing and research and development capacity.